# SOS1

Source: https://onco.cc/targets/sos1/  
OnCo record `sos1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SOS1 (Son of sevenless homolog 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Skin cancer, Breast cancer and 1 more.

## Summary

Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF. Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes affected pathway 0.83, literature 0.94, genetic association 0.00, somatic mutation 0.91, animal model 0.38). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Endometrial Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: SOS Ras/Rac guanine nucleotide exchange factor 1; Son of sevenless homolog 1; GF1; GINGF
- Tags: cancer-genes-wave
- Symbol: SOS1
- Class: oncogene
- Biology: Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF. Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity. Locus 2p22.1 (HGNC).
- Where found: Endometrial cancer: Open Targets association 0.53 with endometrial cancer (MONDO_0011962); IntOGen driver in 1 cohort (UCEC); Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898); Breast cancer: Open Targets association 0.53 with breast cancer (MONDO_0007254); Gastric & gastro-oesophageal junction cancer: Open Targets association 0.51 with gastric cancer (MONDO_0001056)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:11187: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11187
- UniProt Q07889: https://www.uniprot.org/uniprotkb/Q07889/entry
- NCBI Gene 6654: https://www.ncbi.nlm.nih.gov/gene/6654
- Ensembl ENSG00000115904: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115904

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- pathways: [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)

---
JSON: https://onco.cc/api/v1/entities/sos1.json